Tay-Sachs Disease Risk: Ashkenazi Jewish Predominance and Carrier Genetics

Tay-Sachs disease (TSD) shows striking ethnic disparity due to founder effects and genetic drift.

Population Carrier Frequencies

Population	Carrier Frequency	Key Mutations
Ashkenazi Jewish	1 in 27–30	1278insTATC (78%), IVS12+1G>C (20%)
French Canadian (SE Quebec)	1 in 15–20	7.6 kb deletion, IVS12+1G>C
Cajun (Louisiana)	1 in 30–40	1278insTATC
Irish American	1 in 50	Various
General population	1 in 250–300	Hundreds of private mutations

Why Ashkenazi Jews?

• Founder effect: Mutation arose ~40 generations ago in a small founding population.
• Genetic drift: Population bottlenecks (pogroms, migrations) amplified allele frequency.
• Possible heterozygote advantage: Hypothesized resistance to tuberculosis (unproven); no consensus.

Inheritance Mathematics

• Autosomal recessive: Both parents must be carriers.
• Carrier couple risk: 25% affected, 50% carrier, 25% unaffected non-carrier per pregnancy.
• If one partner is Ashkenazi (1/30 carrier) and other non-Jewish (1/300): risk = (1/30)×(1/300)×(1/4) = 1/36,000.

Screening Impact

• Community-based carrier screening (since 1971) + prenatal diagnosis → >90% reduction in TSD births in screened populations.
• ACMG now recommends pan-ethnic carrier screening for TSD (among 100+ conditions).

Genetic Counseling Points

• Test the high-risk partner first; if negative, partner testing may be deferred.
• Pseudodeficiency allele (R247W/R249W) causes false enzyme-screen positives; DNA testing resolves.
• Negative targeted panel ≠ zero risk (residual risk from undetected variants).

Ethnicity guides screening strategy, but TSD can occur in any population. Universal sequencing panels are becoming standard.